KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Tax Provisions (2016 - 2025)

CRISPR Therapeutics AG's Tax Provisions history spans 11 years, with the latest figure at -$300000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 125.62% year-over-year to -$300000.0; the TTM value through Dec 2025 reached $2.7 million, down 33.39%, while the annual FY2025 figure was $2.7 million, 33.21% down from the prior year.
  • Tax Provisions for Q4 2025 was -$300000.0 at CRISPR Therapeutics AG, down from $619000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $6.1 million in Q2 2022 and bottomed at -$8.5 million in Q4 2022.
  • The 5-year median for Tax Provisions is $812000.0 (2024), against an average of $543450.0.
  • The largest YoY upside for Tax Provisions was 993.14% in 2021 against a maximum downside of 615.47% in 2021.
  • A 5-year view of Tax Provisions shows it stood at -$4.0 million in 2021, then tumbled by 114.05% to -$8.5 million in 2022, then skyrocketed by 107.72% to $657000.0 in 2023, then skyrocketed by 78.23% to $1.2 million in 2024, then crashed by 125.62% to -$300000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Tax Provisions are -$300000.0 (Q4 2025), $619000.0 (Q3 2025), and $1.3 million (Q2 2025).